Irinotecano Basi

Irinotecan, the active ingredient in Irinotecano Basi, is a Topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is employed to treat colorectal cancer in adult patients. GNH USA supplies Irinotecano Basi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is a chemotherapy agent used primarily in the treatment of colorectal cancer and related disease stages. - Metastatic colorectal cancer: administered in combination regimens to improve response rates and survival. - Colorectal cancer (adjuvant): used after surgery as part of postoperative chemotherapy to reduce recurrence risk. - Advanced solid tumours: occasionally incorporated in clinical protocols for refractory solid tumours where topoisomerase I inhibition is indicated.

Irinotecan can cause a range of adverse reactions that vary in frequency and severity. Common Side Effects: - Neutropenia: reduced white blood cell count, increasing infection risk. - Diarrhea: often severe, may require antidiarrheal therapy. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized tiredness affecting daily activities. - Anemia: decreased red blood cells causing weakness. Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, a medical emergency. - Severe colitis or intestinal perforation from uncontrolled diarrhea. - Hepatotoxicity: elevated liver enzymes or liver dysfunction. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

Before initiating irinotecan therapy, clinicians should assess patient‑specific risk factors and monitor relevant parameters. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia. - Liver function: evaluate hepatic enzymes and bilirubin, adjusting dose if impaired. - Gastrointestinal assessment: screen for bowel obstruction or inflammatory bowel disease. - Concomitant myelosuppressants: use caution when combined with other bone‑marrow‑suppressing agents. - Hypersensitivity: discontinue if signs of severe allergic reaction appear. - Store at controlled room temperature: keep in original packaging, protect from moisture and light.

Irinotecan may interact with other medicines, altering its efficacy or safety profile. Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase SN‑38 exposure, raising toxicity risk. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): reduce SN‑38 clearance, leading to severe neutropenia. - Concurrent high‑dose myelosuppressive chemotherapy: markedly heighten bone‑marrow suppression. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower drug levels, reducing effectiveness. - Anticoagulants (e.g., warfarin): monitor coagulation parameters due to potential bleeding risk. - Diuretics: watch for electrolyte disturbances that could exacerbate toxicity.